This trial is testing a new drug, OP-1250, to see if it is safe and effective against tumors.
- Hormone Receptor-positive Breast Cancer
- HER2-negative Breast Cancer
1 Primary · 0 Secondary · Reporting Duration: Up to one year
2 Treatment Groups
1 of 2
OP-1250 Dose Escalation
1 of 2
94 Total Participants · 2 Treatment Groups
Primary Treatment: OP-1250 · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
In how many different areas is this trial accessible?
"There are 4 sites running this trial at the moment, located in Sarasota, Orlando, Nashville and other locations. If you wish to participate it would be best to select a location nearest to you so as to not incur extensive travel costs." - Anonymous Online Contributor
Are recruitment efforts for this trial still underway?
"That is correct. The clinical trial, which began recruiting on August 13th 2020, is currently looking for 94 patients at 4 different hospitals or medical centres." - Anonymous Online Contributor
How many participants are currently enrolled in this trial?
"The sponsor, Olema Pharmaceuticals, Inc., needs 94 eligible patients to proceed with the trial. The research will be conducted in Advent Health (Orlando, Tennessee) and Florida Cancer Center (Sarasota, Florida)." - Anonymous Online Contributor